Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Goetz, Matthew P ^a,b   Brauch, Hiltrud ^c   Ratain, Mark J ^d   Cox, Nancy J ^d   Nakamura, Yusuke ^d   Weinshilboum, Richard ^b   Ingle, James N ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DNA; GERMLINE DNA; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST TUMOR; CANCER RECURRENCE; DNA EXTRACTION; GENETIC PARAMETERS; GENOTYPE; GERM LINE; HARDY WEINBERG DISTRIBUTION LAW; HUMAN; LETTER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR CELL; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM; NOTE;

BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DNA, NEOPLASM; FEMALE; HUMANS;

EID: 84905166466     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju063     Document Type: Letter

References (15)

1. Schroth W, Goetz M P, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-1436.
2. Regan MM, leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 Trial. J Natl Cancer Inst. 2012;104(6):441-451.
3. Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.
4. Nakamura Y, Ratain MJ, Cox NJ, Mcleod Hl, kroetz Dl, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopau-sal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(16):1264; author reply 1266-1268.
5. Stanton V Jr. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012;104(16):1265-1266; author reply 1266-1268.
6. Pharoah PD, Abraham J, Caldas C. Re: CYP2D6 genotype and tamoxifen response in post-menopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(16):1263-1264; author reply 1266-1268.
7. Brauch H, Schroth W, Goetz M P, et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2013;31(2):176-180.
8. Goetz MP, Suman VJ, Hoskin Tl, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013;19(2):500-507.
9. Rae JM, Regan M, leyland-Jones B, Hayes DF, Dowsett M. CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. J Clin Oncol. 2013;31(21):2753-2755.
10. Ratain MJ, Nakamura Y, Cox NJ. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther. 2013;94(2):185-187.
11. Rae JM. CYP2D6 genotype should not be used to determine endocrine therapy in postmeno-pausal breast cancer patients. Clin Pharmacol Ther. 2013;94(2):183-185.
12. Rae JM, Regan MM, Thibert JN, et al. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst. 2013;105(17):1332-1334.
13. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransfor-mation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318
14. Berry D. CYP2D6 Genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst. 2013;105(17):1267-1269.
15. Province MA, Goetz M P, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014;95(2):216-227.